the swiss times
en_GB English
en_GB English de_DE German fr_FR French es_ES Spanish ar Arabic
the swiss times

Hemotune Secures CHF 14 Million for Clinical Trials

Hemotune Secures CHF 14 Million for Clinical Trials

Tue, Mar 26th 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Photo courtesy of Hemotune

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Related Stories

Swiss Pension Funds Perform Well In Q1 2024
Thumbnail

6 May 2024

Swiss pension funds kick off 2024 with impressive returns, maintaining a strong financial stance despite inflation...

Bern Riots: 11 Policeman Injured & Arrests
Thumbnail

6 May 2024

Unrest at Bern's Schützenmatte results in serious accusations by the regional police chief against rioters. ...

Sandoz Q1 Strong Start To The Year With Biosimilars Growth
Thumbnail

7 May 2024

Sandoz sees a solid financial start in 2024, with biosimilars growing 21%, contributing to a total revenue of $2.5...

Brian Keller Pre-Trail Detention Approved In Zurich
Thumbnail

6 May 2024

Zurich court approves pre-trial detention for Brian Keller, citing "risk of repetition." The 28-year-old faces charges...

Swiss Firm, Montana Aerospace: 2024 Q1 Performance
Thumbnail

8 May 2024

Montana Aerospace AG reports a stellar Q1 2024 with solid financial growth and reconfirmed future guidance....

Swiss Bank Valiant Reports Strong Growth in Q1 2024
Thumbnail

3 May 2024

Swiss Bank Valiant sees a significant profit increase in Q1 2024, with a 28% jump in operating profit....

Garrett Motion $800 Million Notes After Bad Q1
Thumbnail

8 May 2024

Garrett Motion Inc. elevates its offering to $800 million in senior unsecured notes, with a proactive response to its...

Stay in Touch

Noteworthy

Leonteq and Raiffeisen Extend Partnership
Noteworthy
12 April 2024

Leonteq and Raiffeisen Extend Partnership

Jans & The Region Want to Fight Crime Together
Noteworthy
22 April 2024

Jans & The Region Want to Fight Crime Together
the swiss times
A production of UltraSwiss AG, 6340 Baar, Switzerland

Quick Links

Home Privacy GTC Contact Us About Us
Copyright © 2024 UltraSwiss AG 2024 All rights reserved